15 completed, 2 terminated. 17 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 15, Terminated 2 |
| Phase 2 | 3 | Completed 3 |
Follow Chronic Hepatitis C Infection: new trials by email Literature Review of Chronic Hepatitis C Infection trials Research Report on Chronic Hepatitis C Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C Infection | Phase 2 / Phase 3 | Completed | AbbVie | 64 | 2015-10-28 | 2021-10-05 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir, ribavirin - Chronic Hepatitis C Infection | Phase 3 | Terminated | AbbVie | 3 | 2015-07-01 | 2017-12-12 |
| Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients sofosbuvir and daclatasvir, ledipasvir/sofosbuvir - Chronic Hepatitis C Infection | Phase 3 | Completed | Humanity and Health Research Centre | 48 | 2015-05-01 | 2018-03-19 |
| A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil ombitasvir/paritaprevir/ritonavir and dasabuvir, ribavirin - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie | 222 | 2015-04-27 | 2017-08-01 |
| DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) Ledipasvir/Sofosbuvir, Sofosbuvir and Daclatasvir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir - Chronic Hepatitis C Infection, HBV Coinfection | Phase 2 / Phase 3 | Completed | Humanity and Health Research Centre | 23 | 2015-02-01 | 2021-09-01 |
| SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients Sofosbuvir, Daclatasvir - Chronic Hepatitis C Infection | Phase 2 / Phase 3 | Completed | Humanity and Health Research Centre | 106 | 2015-01-01 | 2018-03-19 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir - Chronic Hepatitis C Infection, Compensated Cirrhosis | Phase 3 | Completed | AbbVie | 60 | 2014-09-01 | 2021-07-12 |
| Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection ABT-450/r/ABT-267, Placebo - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie | 363 | 2013-12-01 | 2018-06-06 |
| Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV Pegylated Interferon Lambda-1a, Daclatasvir (DCV), Ribasphere (RBV) - Chronic Hepatitis C Infection | Phase 3 | Terminated | Bristol-Myers Squibb | 453 | 2013-07-11 | 2023-06-13 |
| A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults ABT-450/r/ABT-267, ABT-333, Ribavirin, Pegylated Interferon a-2a (PegINF) - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie | 148 | 2013-06-01 | 2018-06-06 |
| A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection ABT-450/r/ABT-267, ABT-333, Ribavirin, Placebo for Ribavirin - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie | 305 | 2013-03-01 | 2021-07-12 |
| A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before ABT-450/r/ABT-267, ABT-333, Ribavirin, Telaprevir - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie | 311 | 2013-03-01 | 2018-06-06 |
| A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection ABT-450/r/ABT-267, ABT-333, Ribavirin, Placebo for ribavirin - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 419 | 2012-12-01 | 2021-07-12 |
| A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults ABT-450/r/ABT-267, ABT-333, Ribavirin, Placebo for ABT-450/r/ABT-267 - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 395 | 2012-11-01 | 2021-08-02 |
| A Study to Evaluate Chronic Hepatitis C Infection ABT-450/r/ABT-267, ABT-333, Ribavirin, Placebo for ABT-450/r/ABT-267 - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 636 | 2012-11-01 | 2021-07-12 |
| A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV) - Chronic Hepatitis C Infection, Compensated Cirrhosis | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 381 | 2012-10-01 | 2021-07-12 |
| A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C ABT-450/r/ABT-267, ABT-333, Ribavirin - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 187 | 2012-08-01 | 2021-07-12 |
Hepatitis C (12) · Hepatitis C, Chronic (9) · Fibrosis (1) · Hepatitis, Chronic (1)
Blood-Borne Infections (12) · Communicable Diseases (12) · Digestive System Diseases (12) · Flaviviridae Infections (12) · Hepatitis (12) · Hepatitis, Viral, Human (12) · Infections (12) · Liver Diseases (12) · RNA Virus Infections (12) · Virus Diseases (12) · Chronic Disease (10) · Disease Attributes (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Hepatitis, Chronic (9)
ombitasvir (13) · paritaprevir (13) · Ribavirin (12) · dasabuvir (12) · Viekira Pak (11) · daclatasvir (4) · Sofosbuvir (3) · Ritonavir (2) · ledipasvir (2) · ledipasvir, sofosbuvir drug combination (2) · telaprevir (2) · Tenofovir (1) · entecavir (1) · peginterferon lambda-1a (1)
AbbVie (8) · AbbVie (prior sponsor, Abbott) (5) · Humanity and Health Research Centre (3) · Bristol-Myers Squibb (1)
China (3) · Belgium (2) · Germany (2) · Spain (2) · United States (2) · Argentina (1) · Canada (1) · France (1) · Italy (1) · Mexico (1) · Poland (1) · Puerto Rico (1) · Russia (1) · United Kingdom (1)
Roger Trinh, MD (2) · Yan Luo, MD (2) · Dan Cohen, MD (1) · George KK Lau, MD (1) · George Lau, M.D. (1) · George Lau, MD (1) · Jeff Enejosa, MD (1) · Jeffrey Enejosa, MD (1) · Nancy Shulman, MD (1) · Nori Yachi (1) · Yan Luo, MD, PhD (1)
PMID 29377566, PMID 26321288, PMID 24720679, PMID 24720703, PMID 24818763, PMID 26147154, PMID 26248955, PMID 27084721, PMID 27115431, PMID 27762283, PMID 28282271, PMID 32451952
2015 (2), 2014 (1)